Clinicopathological and molecular differences between stage IV screen-detected and interval colorectal cancers in the Flemish screening program

Bibliographic Details
Title: Clinicopathological and molecular differences between stage IV screen-detected and interval colorectal cancers in the Flemish screening program
Authors: Isabelle Neefs, Thuy Ngan Tran, Allegra Ferrari, Sharon Janssens, Koen Van Herck, Ken Op de Beeck, Guy Van Camp, Marc Peeters, Erik Fransen, Sarah Hoeck, Guido Van Hal
Source: Frontiers in Oncology, Vol 14 (2024)
Publisher Information: Frontiers Media S.A., 2024.
Publication Year: 2024
Collection: LCC:Neoplasms. Tumors. Oncology. Including cancer and carcinogens
Subject Terms: colorectal cancer, clinicopathological differences, interval cancer, molecular alterations, screening, Neoplasms. Tumors. Oncology. Including cancer and carcinogens, RC254-282
More Details: IntroductionInterval cancer (IC) is an important quality indicator in colorectal cancer (CRC) screening. Previously, we found that fecal immunochemical test (FIT) ICs are more common in women, older age, right-sided tumors, and advanced stage. Here, we extended our existing stage IV patient cohort with clinicopathological and molecular characteristics, to identify factors associated with FIT-IC.MethodsLogistic regression models were fit to identify variables associated with the odds of having a stage IV FIT-IC. Multivariate models were corrected for gender, age, and location.ResultsA total of 292 screen-detected (SD) CRCs and 215 FIT-IC CRCs were included. FIT-IC CRC had 5 fold higher odds to be a neuroendocrine (NET) tumor and 2.5 fold higher odds to have lymphovascular invasion. Interestingly, some variables lost significance upon accounting for location. Thus, tumor location is a critical covariate that should always be included when evaluating factors related to FIT-IC.ConclusionsWe identified NETs and lymphovascular invasion as factors associated with increased odds of having a stage IV FIT-IC. Moreover, we highlight the importance of tumor location as a covariate in evaluating FIT-IC related factors. More research across all stages is needed to clarify how these insights might help to optimize the Flemish CRC screening program.
Document Type: article
File Description: electronic resource
Language: English
ISSN: 2234-943X
Relation: https://www.frontiersin.org/articles/10.3389/fonc.2024.1409196/full; https://doaj.org/toc/2234-943X
DOI: 10.3389/fonc.2024.1409196
Access URL: https://doaj.org/article/6553165151cc4e56920d8a1a41ed2826
Accession Number: edsdoj.6553165151cc4e56920d8a1a41ed2826
Database: Directory of Open Access Journals
More Details
ISSN:2234943X
DOI:10.3389/fonc.2024.1409196
Published in:Frontiers in Oncology
Language:English